

Successful treatment for acute prosthetic joint infection due to MRSA and *Candida albicans*: a case report and literature review

Yong Xiang¹
Yi-Yi Xuan²
Guangheng Li¹

¹Department of Orthopedic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China;

²Department of Rheumatology and Immunology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China

Abstract: Methicillin-resistant *Staphylococcus aureus* (MRSA) and *Candidal* prosthetic joint infections (PJIs) are very rare, and the optimal management for these patients is still unknown. A 54-year-old man with traumatic arthritis due to previous electric injury successfully retained the implant despite the successive infection with MRSA and *Candida albicans* after total knee arthroplasty (TKA). Continuous lavage with vancomycin was used to control MRSA infection and repeated local washout plus oral swallow with voriconazole tablet were administered to eradicate *C. albicans*. Additional three reported cases were identified by the criteria of selecting patients with concomitant and/or successive MRSA and *Candidal* PJIs. Different methods were applied with variable outcomes. Therefore, several risk factors such as intra-articular corticosteroid injection, high frequency of door openings in the operating room, excessive blood loss and allogeneic red blood cell transfusions should be avoided. Debridement, antibiotics and implant retention (DAIR) can be an alternative in dedicated patients to control acute MRSA and *Candidal* PJIs. Particularly, repeated intra-articular washout with susceptible drugs and a prolonged duration of oral antibiotics was essential for microbial control.

Keywords: methicillin-resistant *Staphylococcus aureus*, *Candida*, prosthetic joint infection, arthroplasty

Introduction

Methicillin-resistant *Staphylococcus aureus* (MRSA) and *Candidal* prosthetic joint infections (PJIs) have presented a serious concern for surgeons and a disaster for patients.¹⁻⁶ There is no guideline of the optimal treatment for these patients. Several treatment methods to control bacterial and fungal infections have been reported before, including antibiotics; debridement, antibiotics and implant retention (DAIR); resection arthroplasty (RA); one-stage revision (OSR); and two-stage revision (TSR); but the outcomes vary. DAIR has many advantages over RA and delay reimplantation in acute PJI: fewer operations, less expense, conservation of bone stock and better function.⁷ Successful treatment of MRSA and *Candidal* PJI has been reported before,^{2,7-15} but definitive information regarding therapy of the specific group of patients is limited. In this case report, we describe a single case and summarize previously reported cases to clarify the characteristics and explore successful treatment experience in patients with MRSA and *Candidal* PJI.

Patients and methods

Case report

On June 12, 2017, a 54-year-old man was diagnosed with extensive post-traumatic arthritis with apparent pain and disability in his left knee, which caused a limping

Correspondence: Guangheng Li
Department of Orthopedic Surgery,
The First Affiliated Hospital of
Zhengzhou University, Zhengzhou
City 450000, Henan Province,
People's Republic of China
Tel +86 138 0389 3729
Email liguangheng@hotmail.com

gait and seriously affected his daily life. The patient experienced a serious electrical injury in March 2016 and received 4 operations including skin grafting and other multiple surgeries for left patellar dislocation. Neither history of autoimmune diseases, such as systemic lupus erythematosus or rheumatoid arthritis, nor hypertension, diabetes mellitus, or congestive heart failure was there. On examination, the patient was observed to have an 8-cm² area of epidermal scar over the right knee and a 15-cm² area of myocutaneous flap (Figure 1A) over the medial aspect of the left knee just proximal to the joint line. There was a slight left knee joint effusion and patella baja, but no erythema or elevated skin temperature around the left knee joint. The left knee range of motion (ROM) was 0°–10°. Routine preoperative laboratory tests revealed that white blood cell (WBC) count, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were all within normal limits. Radiographs demonstrated severe degenerative arthritis of the left knee with patella baja and bony fusion of bilateral femoral condyle (Figure 2A–C).

The patient underwent total knee arthroplasty (TKA) with a cemented, hinged implant (AK medical business; LINK® Endo-Model® Hinge Knee Prosthesis, Barkhausenweg/Hamburg, Germany) on June 24, 2017. Tibial tuberosity osteotomy (TTO) was performed to obtain proper surgical exposure, avoid damage to the extensor muscle and increase the mobility of the knee joint. Intravenous injection of 1 g Shiomarin (Latamoxef, Haikou/Hainan, China) was used as prophylactic antibiotic before the surgical incision. The operation has lasted for 4 h. The blood loss was 300 mL and fluid resuscitation was 2,000 mL. Three units of packed red blood cells and 200 mL of fresh frozen plasma were transfused intraoperatively. The patient had a benign

postoperative course in the first few postoperative days with a knee ROM in 0°–90°. Latamoxef 1 g was intravenously administered twice a day until the 8th postoperative day when he complained about pain, moderate swelling without fever, chills, nausea and vomiting. Poor wound healing, persistently profuse drainage and wound dehiscence were observed in the surgical site 2 days later (the 10th postoperative day). A sterile needle aspiration was performed, with removal of 40 mL dark bloody fluid (Figure 1B). The pathogen of the fluid specimens was MRSA. Drug sensitivity test revealed the minimum inhibitory concentration (MIC) of Vancocin (vancomycin hydrochloride) for the organism was 1 µg/mL. At this time, The WBC count was $8.9 \times 10^9/L$ (normal range, $[3.5-9.5] \times 10^9/L$), CRP was 100.5 mg/L (normal range, $[0-5] \text{ mg/L}$) and ESR was 44 mm/h (normal range, $[0-15] \text{ mm/h}$). A diagnosis of acute PJI was made, and 0.5 g vancomycin hydrochloride was intravenously administered every 12 h. The patient was scheduled for urgent debridement and irrigation. Plain film radiographs did not reveal any evidence of loosening, lucency or osteolysis around the prosthetic components.

On July 15, 2017 the patient underwent surgery comprising: (1) complete debridement including the removal of all necrotic and fibrous tissue and proliferative inflammatory synovialis; (2) 3 samples of the suspected infected tissue were sent for microbiological evaluation; (3) polyethylene liner was exchanged; (4) washout with 100 mL of 3% hydrogen peroxide, soak in 300–400 mL 10% polyvinylpyrrolidone-iodine (PVP-I, Chengdu/Sichuan, China) for 15 min, exhaustive irrigation was carried out with 10 L saline mixed with gentamicin by using pulsed lavage and (5) indwelling the inlet and outlet tubes for further continuous lavage with saline




Figure 1 (A) The wound of the patient was in a good condition at the third postoperative day; (B) a sterile needle aspiration was performed, with removal of 40 mL of dark bloody fluid at the ninth postoperative day; (C) the yellowish fluid with tofu-like tissue was observed around sinus tract in the knee joint.




Figure 2 (A) The full length plain of lower extremity; (B) the lateral plain of the left knee; (C) the negative plain X-ray of the left knee. (A–C) Severe degenerative arthritis of the left knee with a low patella and bony fusion of femoral condyle. At 5 months of follow-up the radiographs show, (D) the full length plain of lower extremity; (E) the lateral plain of the left knee; (F) the positive film of the left knee. All the film of left knee revealed the prosthesis was well-fixed without loosening.

and vancomycin hydrochloride (100 µg/mL). Intraoperative findings verified that all components were extremely well-fixed without loosening. Vancomycin hydrochloride was administered intravenously every 12 h combined with continuous lavage. The indwelling drains were removed on the 19th day (August 3, 2017), when the incision wound was dry, and CRP and ESR returned to normal levels, after the debridement and irrigation surgery. There was no tenderness or swelling around the joint, and the infection was regarded as resolved. The patient was ready to be discharged with oral compound Sulfamethoxazole (sinomine; Minhang/Shanghai, China), but he complained about the evaluated skin temperature, pain and increasing swelling in the left knee joint again 2 days later (August 5, 2017). A sinus tract communicating with knee joint was seen, around which was the yellowish fluid with tofu-like tissue (Figure 1C). It did not appear to be synovial in nature so it was collected for pathogen and drug sensitivity test, which was subsequently identified as *Candida albicans*. The result was initially regarded as a contamination but repeated punctures confirmed the infection of *C. albicans*. The MIC of fluconazole for *C. albicans* was 1 µg/mL. At that point, the WBC count was $2.8 \times 10^9/L$, the CRP was 4.3 mg/L and the

ESR was 35 mm/h. The patient refused surgical treatment, therefore vancomycin hydrochloride was stopped and he was treated with fluconazole (Datong/Sanxi, China) intravenously (100 mg/d) and daily aspirations, local washout with 100 mL fluconazole (1 mg/mL), which was 1,000 times higher than MIC and finally intra-articular injection of 10 mL fluconazole (1 mg/mL). Eighteen days later (August 24, 2017), the susceptibility of fluconazole changed from “S (susceptible)” to “I (intermediate)”. Thereafter we replaced fluconazole with voriconazole (Chengdu/Sichuan, China) based on the susceptibility test. The MIC of voriconazole for *C. albicans* was 0.06 µg/mL. Antibiotic treatment regimens were as follows: oral voriconazole (200 mg/d) was administered; local washout with voriconazole (2 mg/mL) every other day for the first 3 weeks and then adjusted to every 5 days for the next 3 weeks.

On October 20, 2017, arthrocentesis was performed to examine the effect of the treatment method so far. The results of fungal stains, gram stains and bacterial cultures were all negative. The patient had no systematic discomfort and no local erythema, no local heat, no resting pain, no discharge sinus in the infected joint. The patient was discharged with oral voriconazole (200 mg/d) for 6 months. After 5 months

of follow-up, the film of the left knee revealed the prosthesis was well-fixed (Figure 2D–F) and laboratory findings were normal. Currently, the patient is on a continued 6-month oral antifungal treatment.

Literature review

Using the key words “fungal”, “*candida*”, “Methicillin-resistant *Staphylococcus aureus*”, “MRSA”, “prosthetic joint infection” and “arthroplasty”, we searched CINAHL, MEDLINE (National Library of Medicine, Bethesda, MD) and Web of Science, Cochrane systematic review databases for cases with PJI associated to MRSA and *Candida*. A secondary search of references cited in the articles related to our topics was performed. Four cases diagnosed as concomitant and/or successive MRSA and *Candidal* PJI, whose data on demographic characteristics, treatment, outcome and follow-up were identified in the English literature. Table 1 summarizes demographic characteristics, treatment, outcome of patients with MRSA and *Candida* PJI. The patients had an average age of 59.75 years (range: 31–88 years), and they had an average body mass index (BMI) of 26.96 kg/m². The involved joint was the hip in 3 (75%) and the knee in 1 (25%). A sinus tract was present in 2 patients (patients 1 and 4). Three patients had one or more underlying systemic diseases, including COPD in 2 patients, chronic renal insufficiency in 1 patient, diabetes mellitus in 2 patients and renal cell carcinoma in 1 patient. The case in our hospital did not have systemic illness, but had a complicated history of multiple electric injury wounds to the extremity with the infected joint. Two patients with a previous history of bacterial infection prior to *C. albicans* were identified, one was MRSA and *Serratia marcescens* infection (patient 1) and the other was MRSA infection (patient 4). Concomitant infection with MRSA and *Candida* was found in 2 patients, 1 was *C. parapsilosis* and MRSA infection and the other was *C. albicans*, MRSA infection. The delay between index surgery and diagnosis varied from 8 days to 4 months and 26 months; it was unavailable in 1 patient. Four patients developed the infection after an average of 2.75 surgeries (range: 1–4). Patient 1 received intravenous injection with antibiotics including flucytosine combined with amphotericin B, but without oral antibiotics. Patients 2 and 3 underwent fluconazole combined with vancomycin hydrochloride intravenously each and oral fluconazole. Our patient received vancomycin hydrochloride intravenously (19 days) for MRSA and fluconazole intravenously (18 days) combined with oral fluconazole and switched to

Table 1 Demographic characteristics, treatment, outcome of patients with MRSA and *Candida* PJI

Case	Age (years)/gender	BMI (kg/m ²)	Joint	Sinus tract	Comorbidities	Previous infection in the same site as the PJI	Time to diagnosis from index surgery	No previous surgery	Preoperative microbe	Intravenous agents	Total duration of IV agent	Surgical treatment	Intra-articular injection	Oral agents/mean time (months)	Outcome follow-up time (months)
1 ⁴⁶	88	NR	Hip	Yes	DM, COPD	MRSA, <i>Ser. Marcescens</i>	NR	4	<i>C. albicans</i>	5-FC+Ampho B	NR	OSR	NR	None	No relapse (>36)
2 ⁴⁷	66	27	Hip	NR	COPD	NR	4 months	2	<i>C. parapsilosis</i> , MRSA	FCZ+VAN	31 days	RA	NR	FCZ > 10.2	RA (>28)
3 ⁴⁷	31	27	Hip	NR	DM, RCC, CRI	NR	26 months	1	<i>C. albicans</i> , MRSA	FCZ+VAN	16 days	TSR	NR	FCZ > 0.5	Dead
4 ⁴⁸	54	26.9	Knee	Yes	None	MRSA	8 days	4	<i>C. albicans</i>	VAN, FCZ	19, 18 days	DAIR	FCZ, then VCZ	VCZ > 1	No relapse (>5)

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; PJI, prosthetic joint infection; BMI, body mass index; IV, intravenous; NR, not reported; DM, diabetes mellitus; 5-FC, flucytosine; Ampho B, amphotericin B; OSR, one-stage revision; FCZ, fluconazole; VAN, vancomycin; RA, resection arthroplasty; RCC, renal cell carcinoma; CRI, chronic renal insufficiency; TSR, two-stage revision; PR, present report; DAIR, debridement, antibiotics and implant retention; VCZ, voriconazole.

voriconazole later for *C. albicans*. Intra-articular injection was used in our patient only. Surgeries were applied including OSR (patient 1), RA (patient 2), TSR (patient 3) and DAIR (patient 4). The final outcome was favorable in 2 (50%) patients with no relapse (patients 1 and 4). But one was positive with RA (patient 2) and another died after TSR (patient 3).

Discussion

This is the first case report of MRSA and *Candidal* PJIs treated with DAIR. PJI is a serious complication of arthroplasty associated with significant mortality.^{16–18} The rarity of MRSA and *Candida* infections limits our understanding of the management and outcome in these patients.¹⁹

The present case had several risk factors including high frequency of door openings in the operating theater,²⁰ fluid resuscitation over 2,000 mL,²¹ 3 units of allogeneic red blood cells and 200 mL fresh frozen plasma transfusion during the operation. The Pulido et al study showed patients receiving allogeneic transfusions were regarded as an independent risk factor for PJI which was 2.1 times more likely to develop PJI compared with no transfusion.²²

In addition, the complexity of arthroplasty, such as the use of hinged implants in our case, may also contribute to high complication rate.²³ Furthermore, the infection rate using a rotating hinge design was enormous with 11% in primary and 9% in revision cases.^{24,25}

Also in our review, these four patients had several identifiable risk factors for PJI, either systemic diseases or local comorbidities, such as poorly controlled diabetes mellitus, male gender, chronic renal disease, diagnosis of post-traumatic arthritis, prior surgical procedure in the affected joint, which was consistent with potential risk factors for development of PJI described in The International Consensus on Periprosthetic Joint Infection.⁴⁸

With incidence of MRSA PJI and *Candidal* PJI being on an upward trend, the management of these patients is a major challenge to most orthopedic surgeons.²⁶ No consensus currently exists on the optimal antibiotic therapy and surgical intervention for PJI due to MRSA and *Candida* species. Although reimplantation protocol resulted in a viable option for patients with infections by common organisms, it might be accompanied by a high recurrence rate, especially in patients with antibiotic resistant organisms.

Our case is unique since the patient had successful eradication of infection by using open debridement, continuous lavage for MRSA infection and intra-articular washout for *C. albicans*. During the debridement operation, washout with

hydrogen peroxide, soaking with 10% PVP-I for 15 min and pulsed lavage was used.

In vitro, PVP-I has been proved to be effective against a wide range of pathogens, including Gram-positive and Gram-negative bacteria, bacillus, protozoa and viruses.^{27,28} Giacometti et al²⁹ demonstrated that PVP-I at the concentration of 1,000 mg/L for 30 min or 10,000 mg/L for 15 min, respectively, was able to inhibit the growth of methicillin sensitive *S. aureus* (MSSA), MRSA and *Pseudomonas aeruginosa*.

In addition, continuous lavage was used after complete debridement in our patient. Mont et al study shows that in patients with acute PJI, multiple debridement and retention of the components can result in low morbidity with high success rates.³⁰ However, Tsumura et al demonstrated that multiple operations would damage the skin and create anxieties in patients but continuous irrigation is an effective method to cure early-stage infection of TKA.³¹ This method might be especially useful in controlling infection and decreasing the number of surgical interventions. It also remains uncertain about when to remove the drainage tube, how to confirm the absence of organism and how to prevent superinfection.

More importantly, intra-articular washout combined with oral antifungal agents was performed in our patient to control *C. albicans*. Salvati et al also reported that the proper antibiotic concentration in joint fluid could not be maintained by antibiotic-impregnated cement.^{32–34} However, it had been proved that intra-articular delivery of antibiotics produced peak concentrations that many orders of magnitude higher than intravenous administration and trough concentrations which have remained at the therapeutic dose for 24 h. Similar methods of intra-articular antibiotic delivery have been reported effectively in previous literature to treat acute and chronic-infected TKA.^{35–38} Revision combined with intra-articular vancomycin hydrochloride administration to control infection in MRSA-infected TKA is also shown to be safe and effective.^{39,40} OSR combined with intra-articular delivery of fluconazole was reported to successfully treat fungal PJI.¹⁶ However, to our knowledge, this case is the first to adopt this intra-articular delivery method of voriconazole without the removal of the implant. The agents must be adjusted according to the results of susceptibility testing because fungal biofilms are more complex than other pathogens.⁴¹ In our treatment experience, voriconazole is more effective than fluconazole when applied in the treatment of *C. albicans* infections. The reason may be that voriconazole is a more active regimen to suppress the recovery of viable colony-forming units (CFUs) from the model at 24 h. In addition, voriconazole-exposed catheters exhibited a significantly lower burden of organisms,

revealed by sonicated catheter cultures at 48 h, versus the fluconazole for isolated *C. albicans*.⁴²

Lastly, the authors consider whether a prolonged time of local susceptible antibiotics delivery in acute PJI might be the major issue in treatment and induce a better outcome than radical revision surgery, which has also been shown effective in some of the earlier in vitro and clinical reports, but it needs further study to prove the hypothesis.^{43,44} Therefore, risk factors like intra-articular corticosteroid injection, high frequency of door openings in the operating room,⁴⁵ excessive blood loss and allogeneic red blood cell transfusion should be avoided, and our method (DAIR) could be an alternative to tackle the challenge of MRSA and *Candidal* PJI. Particularly, repeated intra-articular washout with susceptible drugs and a prolonged duration of oral antibiotics was essential for microbial control.

Consent

The patient provided written informed consent specifically for the publication of the case details and any accompanying images.

Acknowledgment

This work was supported by the National Natural Science Foundation of China (No. 81472136).

Disclosure

The authors report no conflicts of interest in this work.

References

- Sousa RJ, Barreira PM, Leite PT, Santos AC, Ramos MH, Oliveira AF. Preoperative *Staphylococcus aureus* screening/decolonization protocol before total joint arthroplasty – results of a small prospective randomized trial. *J Arthroplasty*. 2016;31(1):234–239.
- Salgado CD, Dash S, Cantey JR, Marculescu CE. Higher risk of failure of methicillin-resistant *Staphylococcus aureus* prosthetic joint infections. *Clin Orthop Relat Res*. 2007;461:48–53.
- Senneville E, Joulie D, Legout L, et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to *Staphylococcus aureus*. *Clin Infect Dis*. 2011;53(4):334–340.
- Kuiper JW, Willink RT, Moojen DJ, van den Bekerom MP, Colen S. Treatment of acute periprosthetic infections with prosthesis retention: Review of current concepts. *World J Orthop*. 2014;5(5):667–676.
- Jakobs O, Schoof B, Klatte TO, et al. Fungal periprosthetic joint infection in total knee arthroplasty: a systematic review. *Orthop Rev (Pavia)*. 2015;7(1):5623.
- Shaikh AA, Ha C-W, Park Y-G, Park Y-B. Two-stage approach to primary TKA in infected arthritic knees using intraoperatively molded articulating cement spacers. *Clin Orthop Relat Res*. 2014;472(7):2201–2207.
- Bradbury T, Fehring TK, Taunton M, et al. The fate of acute methicillin-resistant *Staphylococcus aureus* periprosthetic knee infections treated by open debridement and retention of components. *J Arthroplasty*. 2009;24(6 Suppl):101–104.
- Cushing RD, Fulgenzi WR. Synovial fluid levels of fluconazole in a patient with *Candida parapsilosis* prosthetic joint infection who had an excellent clinical response. *J Arthroplasty*. 1997;12(8):950.
- Simonian PT, Brause BD, Wickiewicz TL. *Candida* infection after total knee arthroplasty. Management without resection or amphotericin B. *J Arthroplasty*. 1997;12(7):825–829.
- Brooks DH, Puppato F. Successful salvage of a primary total knee arthroplasty infected with *Candida parapsilosis*. *J Arthroplasty*. 1998;13(6):707–712.
- Wada M, Baba H, Imura S. Prosthetic knee *Candida parapsilosis* infection. *J Arthroplasty*. 1998;13(4):479–482.
- Siddiqui MM, Lo NN, Ab Rahman S, Chin PL, Chia SL, Yeo SJ. Two-year outcome of early deep MRSA infections after primary total knee arthroplasty: a joint registry review. *J Arthroplasty*. 2013;28(1):44–48.
- Triantafyllopoulos GK, Soranoglou V, Memtsoudis SG, Poultsides LA. Implant retention after acute and hematogenous periprosthetic hip and knee infections: Whom, when and how? *World J Orthop*. 2016;7(9):546–552.
- Aboltins CA, Page MA, Buising KL, et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. *Clin Microbiol Infect*. 2007;13(6):586–591.
- Chiu FY, Chen CM. Surgical debridement and parenteral antibiotics in infected revision total knee arthroplasty. *Clin Orthop Relat Res*. 2007;461:130–135.
- Ji B, Zhang X, Xu B, Guo W, Mu W, Cao L. Single-stage revision for chronic fungal periprosthetic joint infection: An average of 5 years of follow-up. *J Arthroplasty*. 2017;32(8):2523–2530.
- Zawadzki N, Wang Y, Shao H, et al. Readmission due to infection following total hip and total knee procedures: A retrospective study. *Medicine (Baltimore)*. 2017;96(38):e7961.
- Kuiper JW, van den Bekerom MP, van der Stappen J, Nolte PA, Colen S. 2-stage revision recommended for treatment of fungal hip and knee prosthetic joint infections. *Acta Orthop*. 2013;84(6):517–523.
- Matsumoto T, Ishida K, Tsumura N, et al. Treatment of 50 deep infections after total knee arthroplasty. *Orthopedics*. 2015;38(6):e529–e535.
- Panahi P, Stroh M, Casper DS, Parvizi J, Austin MS. Operating room traffic is a major concern during total joint arthroplasty. *Clin Orthop Relat Res*. 2012;470(10):2690–2694.
- Everhart JS, Altneu E, Calhoun JH. Medical comorbidities are independent preoperative risk factors for surgical infection after total joint arthroplasty. *Clin Orthop Relat Res*. 2013;471(10):3112–3119.
- Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: the incidence, timing, and predisposing factors. *Clin Orthop Relat Res*. 2008;466(7):1710–1715.
- Guenoun B, Latargez L, Freslon M, Defossez G, Salas N, Gayet LE. Complications following rotating hinge Endo-Modell (Link) knee arthroplasty. *Orthop Traumatol Surg Res*. 2009;95(7):529–536.
- Steckel H, Klinger HM, Baums MH, Schultz W. Long-term results of the Blauth knee prosthesis – current status of hinged knee prostheses. *Z Orthop Ihre Grenzgeb*. 2005;143(1):30–35.
- Petrou G, Petrou H, Tilkeridis C, et al. Medium-term results with a primary cemented rotating-hinge total knee replacement. A 7- to 15-year follow-up. *J Bone Joint Surg Br*. 2004;86(6):813–817.
- Gould IM, Reilly J, Bunyan D, Walker A. Costs of healthcare-associated methicillin-resistant *Staphylococcus aureus* and its control. *Clin Microbiol Infect*. 2010;16(12):1721–1728.
- Messenger S, Goddard PA, Dettmar PW, Maillard J-Y. Comparison of two in vivo and two ex vivo tests to assess the antibacterial activity of several antiseptics. *J Hosp Infect*. 2004;58(2):115–121.
- Wutzler P, Sauerbrei A, Klöcking R, Brögmann B, Reimer K. Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine. *Antiviral Res*. 2002;54(2):89–97.
- Giacometti A, Cirioni O, Greganti G, et al. Antiseptic compounds still active against bacterial strains isolated from surgical wound infections despite increasing antibiotic resistance. *Eur J Clin Microbiol Infect Dis*. 2002;21(7):553–556.
- Mont MA, Waldman B, Banerjee C, Pacheco IH, Hungerford DS. Multiple irrigation, debridement, and retention of components in infected total knee arthroplasty. *J Arthroplasty*. 1997;12(4):426–433.

31. Tsumura H, Ikeda S, Ono T, Itonaga I, Taira H, Torisu T. Synovectomy, debridement, and continuous irrigation for infected total knee arthroplasty. *Int Orthop*. 2005;29(2):113–116.
32. Salvati EA, Callaghan JJ, Brause BD, Klein RF, Small RD. Reimplantation in infection. Elution of gentamicin from cement and beads. *Clin Orthop Relat Res*. 1986;(207):83–93.
33. Anguita-Alonso P, Rouse MS, Piper KE, Jacofsky DJ, Osmon DR, Patel R. Comparative study of antimicrobial release kinetics from polymethylmethacrylate. *Clin Orthop Relat Res*. 2006;445:239–244.
34. Haleem AA, Berry DJ, Hanssen AD. Mid-term to long-term followup of two-stage reimplantation for infected total knee arthroplasty. *Clin Orthop Relat Res*. 2004;(428):35–39.
35. Whiteside LA, Nayfeh TA, LaZear R, Roy ME. Reinfected revised TKA resolves with an aggressive protocol and antibiotic infusion. *Clin Orthop Relat Res*. 2012;470(1):236–243.
36. Davenport K, Traina S, Perry C. Treatment of acutely infected arthroplasty with local antibiotics. *J Arthroplasty*. 1991;6(2):179–183.
37. Perry CR, Hulsey RE, Mann FA, Miller GA, Pearson RL. Treatment of acutely infected arthroplasties with incision, drainage, and local antibiotics delivered via an implantable pump. *Clin Orthop Relat Res*. 1992;(281):216–223.
38. Fukagawa S, Matsuda S, Miura H, Okazaki K, Tashiro Y, Iwamoto Y. High-dose antibiotic infusion for infected knee prosthesis without implant removal. *J Orthop Sci*. 2010;15(4):470–476.
39. Whiteside LA, Peppers M, Nayfeh TA, Roy ME. Methicillin-resistant *Staphylococcus aureus* in TKA treated with revision and direct intra-articular antibiotic infusion. *Clin Orthop Relat Res*. 2011;469(1):26–33.
40. Whiteside LA, Roy ME, Nayfeh TA. Intra-articular infusion: a direct approach to treatment of infected total knee arthroplasty. *Bone Joint J*. 2016;98-B(1 Suppl A):31–36.
41. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen *Candida albicans*: development, architecture, and drug resistance. *J Bacteriol*. 2001;183(18):5385–5394.
42. Lewis RE, Kontoyiannis DP, Darouiche RO, Raad II, Prince RA. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of *Candida* catheter-related bloodstream infection. *Antimicrob Agents Chemother*. 2002;46(11):3499–3505.
43. Dusane DH, Diamond SM, Knecht CS, et al. Effects of loading concentration, blood and synovial fluid on antibiotic release and anti-biofilm activity of bone cement beads. *J Control Release*. 2017;248:24–32.
44. Howlin RP, Brayford MJ, Webb JS, Cooper JJ, Aiken SS, Stoodley P. Antibiotic-loaded synthetic calcium sulfate beads for prevention of bacterial colonization and biofilm formation in periprosthetic infections. *Antimicrob Agents Chemother*. 2015;59(1):111–120.
45. Sadrizadeh S, Pantelic J, Sherman M, Clark J, Abouali O. Airborne particle dispersion to an operating room environment during sliding and hinged door opening. *J Infect Public Health*. 2018.
46. Klatte TO, Kendoff D, Kamath AF, et al. Single-stage revision for fungal peri-prosthetic joint infection: A single-centre experience. *Bone Joint J*. 2014;96-B(4):492–496.
47. Ueng SW, Lee CY, Hu CC, Hsieh PH, Chang Y. What is the success of treatment of hip and knee candidal periprosthetic joint infection? *Clin Orthop Relat Res*. 2013;471(9):3002–3009.
48. Zmistowski B, Della Valle C, Bauer TW, et al. Diagnosis of periprosthetic joint infection. *J Orthop Res*. 2014;32:S98–S107.

Therapeutics and Clinical Risk Management

Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS,

Submit your manuscript here: <http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal>

Dovepress

EMBASE, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.